Enriqueta Felip, MD, PhD, discusses the phase 3 3475A-D77 study of subcutaneous pembrolizumab plus chemotherapy in metastatic non–small cell lung cancer.

Researchers conducted a meta-analysis of studies to explore the efficacy and safety of pembrolizumab alone and in combination with chemotherapy for the treatment of gastric and GEJ cancers.

Researchers Uncover Link Between Omega 6 Fatty Acid and Aggressive Breast CancerLinoleic acid, an omega-6 fatty acid enhanced ...

A new form of tumor infiltrating lymphocyte therapy, a form of personalized cancer immunotherapy, improved the treatment’s ...

Enfortumab vedotin plus pembrolizumab in advanced bladder cancer: hint of major added benefit. Patients for whom cisplatin-based therapy is unsuitable live significantly longer with the new drug ...

Ociperlimab is described as a humanised IgG1 monoclonal antibody with the potential to enhance T cell-mediated immune ...

Pembrolizumab plus concurrent chemoradiotherapy shows ongoing antitumor activity after about 5 years of follow-up in patients ...

Yelena Y. Janjigian, MD, discusses the long-term survival data from the KEYNOTE-811 trial of pembrolizumab plus trastuzumab ...

MSD’s monoclonal antibody, indicated for 15 types of cancer, smashed industry records with sales of $27.3 billion in 2024, ...

Pembrolizumab shows clinical promise as a treatment for mycosis fungoides and Sézary syndrome, achieving a response in nearly ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

NIH trial shows new form of TIL therapy effective against colon, rectum, pancreas, and bile duct tumors.